These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 32224164)

  • 1. COVID-19 and diabetes: Can DPP4 inhibition play a role?
    Iacobellis G
    Diabetes Res Clin Pract; 2020 Apr; 162():108125. PubMed ID: 32224164
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?
    Krejner-Bienias A; Grzela K; Grzela T
    J Diabetes; 2020 Sep; 12(9):703-704. PubMed ID: 32388906
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
    Drucker DJ
    Endocr Rev; 2020 Jun; 41(3):. PubMed ID: 32294179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
    Solerte SB; Di Sabatino A; Galli M; Fiorina P
    Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of COVID-19 on people with diabetes.
    Bellido V; Pérez A
    Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(6):355-356. PubMed ID: 32475769
    [No Abstract]   [Full Text] [Related]  

  • 8. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.
    Mozafari N; Azadi S; Mehdi-Alamdarlou S; Ashrafi H; Azadi A
    Med Hypotheses; 2020 Oct; 143():110111. PubMed ID: 32721805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is DPP4 inhibition a comrade or adversary in COVID-19 infection.
    Dalan R
    Diabetes Res Clin Pract; 2020 Jun; 164():108216. PubMed ID: 32416120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes mellitus and COVID-19: A review and management guidance for South Africa.
    Coetzee A; Taljaard JJ; Hugo SS; Conradie M; Conradie-Smit M; Dave JA
    S Afr Med J; 2020 Jun; 110(8):761-766. PubMed ID: 32880304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin: a potential drug for the treatment of COVID-19?
    Bardaweel SK; Hajjo R; Sabbah DA
    Acta Pharm; 2021 Jun; 71(2):175-184. PubMed ID: 33151168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
    Chen CF; Chien CH; Yang YP; Chou SJ; Wang ML; Huo TI; Lin CC
    J Chin Med Assoc; 2020 Aug; 83(8):710-711. PubMed ID: 32349031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.
    Strollo R; Maddaloni E; Dauriz M; Pedone C; Buzzetti R; Pozzilli P
    Diabetes Res Clin Pract; 2021 Jan; 171():108444. PubMed ID: 32946854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?".
    Kokic Males V
    Diabetes Res Clin Pract; 2020 May; 163():108163. PubMed ID: 32333972
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? - GLP-1 might play one too.
    Morin N
    Diabetes Res Clin Pract; 2020 Jun; 164():108160. PubMed ID: 32333969
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes and COVID-19 : Disease-Management-People.
    Peric S; Stulnig TM
    Wien Klin Wochenschr; 2020 Jul; 132(13-14):356-361. PubMed ID: 32435867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications.
    Barchetta I; Cavallo MG; Baroni MG
    Diabetes Res Clin Pract; 2020 May; 163():108165. PubMed ID: 32333966
    [No Abstract]   [Full Text] [Related]  

  • 19. DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
    Strollo R; Pozzilli P
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3330. PubMed ID: 32336007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed.
    Wang A; Zhao W; Xu Z; Gu J
    Diabetes Res Clin Pract; 2020 Apr; 162():108118. PubMed ID: 32179126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.